E. Quoix

J. Soria, D. Moro-Sibilot, M. Wislez, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

(I!1Rj review Small Cell Lung Cancer Presenting as a Solitary Pulmonary Nodule*

E. Quoix, N. Wolkove, Harvey Kreisnzan, 2017 .

Small cell lung cancer presenting as a solitary pulmonary nodule.

H. Kreisman, E. Quoix, N. Wolkove, 1990, Cancer.

International differences in epidemiology of lung adenocarcinoma.

M. Rossignol, A. Charloux, A. Purohit, 1997, Lung cancer.

Phase I / II study of neoadjuvant bevacizumab , erlotinib and 5-fl uorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer

I. Bièche, J. Solassol, H. Blons, 2013 .

Small cell carcinoma of the pleura. A case report.

E. Quoix, B. Gasser, G. Pauli, 1996, Lung cancer.

Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study.

E. Lemarié, B. Milleron, E. Quoix, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of small-cell lung cancer on protocol: potential bias of results.

H. Kreisman, E. Quoix, N. Wolkove, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and Validation of a Simplified Prognostic Score in SCLC

O. Molinier, J. Daurès, J. Pujol, 2020, JTO clinical and research reports.

Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994

G. Hédelin, A. Purohit, E. Quoix, 2001, British Journal of Cancer.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)

J. Pignon, B. Chetaille, J. Solassol, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Small cell lung cancer presenting as a solitary pulmonary nodule

H. Kreisman, E. Quoix, N. Wolkove, 1990, Chest.

Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).

H. Groen, J. Rigas, D. Planchard, 2015 .

First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule.

E. Lemarié, D. Moro-Sibilot, E. Quoix, 2005, Lung cancer.

Women and small cell lung cancer: social characteristics, medical history, management and survival: a retrospective study of all the male and female cases diagnosed in Bas-Rhin (Eastern France) between 1981 and 1994.

G. Hédelin, A. Purohit, E. Quoix, 2003, Lung cancer.

Impact of adjuvant chemotherapy (CT) on survival and local-control in non-small cell lung cancer (NSCLC): Results of the international adjuvant lung cancer trial (IALT)

R. Arriagada, J. Pignon, R. Gralla, 2004 .

Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma

G. Giaccone, M. Kris, G. Scagliotti, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Professional Exposure to Goats Increases the Risk of Pneumonic-Type Lung Adenocarcinoma: Results of the IFCT-0504-Epidemio Study

N. Girard, P. Vanhems, V. Cottin, 2011, PloS one.

Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.

E. Lemarié, B. Milleron, J. Daurès, 2001, Journal of the National Cancer Institute.

Bronchoplastic lobectomy: do early results depend on the underlying pathology? A comparison between typical carcinoids and primary lung cancer.

E. Quoix, X. Ducrocq, G. Massard, 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue Française.

J. Lafitte, B. Milleron, E. Brambilla, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.

M. Schaeffer, E. Guérin, E. Quoix, 2016, Future oncology.

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)

O. Molinier, P. Dumont, W. Hilgers, 2018, ESMO Open.

Early alternating chemotherapy and radiotherapy schedule in limited disease stage small cell lung cancer.

A. Charloux, A. Purohit, E. Quoix, 1995, European journal of cancer.

Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group.

P. Postmus, D. Carney, A. Planting, 1992, European journal of cancer.

Extensive small-cell lung cancer. A randomized comparison of two chemotheraphy programs with early crossover in instances of failure

T. Chevalier, E. Quoix, P. Chariot, 1992 .

Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry.

E. Quoix, G. Noël, N. Santelmo, 2016, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

French phase III trial of preoperative chemotherapy (PCT) in resectable stage I (except T1N0), II, IIIa non-small cell lung cancer (NSCLC)

E. Lemarié, B. Milleron, S. Chevret, 2000 .

Immunotherapy for non-small-cell lung cancer: current approaches

J. Limacher, E. Quoix, 2014, Current Respiratory Care Reports.

Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.

P. Lamy, J. Pujol, G. Zalcman, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

J. Mazières, W. Hilgers, F. Barlesi, 2021, ESMO open.

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer

I. Bièche, J. Solassol, H. Blons, 2013 .

Radiation-induced lung toxicity predictors: Retrospective analysis of 90 patients treated with stereotactic body radiation therapy for stage I non-small-cell lung carcinoma.

A. Charloux, E. Quoix, G. Noël, 2020, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.

B. Milleron, D. Spaeth, J. Pujol, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osteoblastic Reaction in Non-small Cell Lung Carcinoma and its Association to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Response and Prolonged Survival

B. Milleron, S. Lantuejoul, G. Zalcman, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rare epidermal growth factor receptor (EGFR) mutations in 10,117 patients with non-small cell lung cancer (NSCLC) evaluated by the French ERMETIC IFCT network: Clinical, molecular, and survival data.

J. Solassol, H. Blons, F. Escande, 2012 .

Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations

T. Berghmans, A. Meert, E. Quoix, 2015, European Respiratory Journal.

Asteatotic eczema (‘eczema craquelé’) with histopathological interface dermatitis: a new cutaneous reaction following pemetrexed

D. Lipsker, E. Quoix, B. Cribier, 2012, The British journal of dermatology.

IFCT0401 trial: Phase II study of gefitinib administered as first-line treatment in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC): Final results on efficacy and survival

B. Milleron, J. Soria, D. Moro-Sibilot, 2007 .

Salvage Therapy in Non-Small Cell Lung Cancer

E. Quoix, B. Mennecier, 2004 .

LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928)

M. Socinski, E. Smit, Gregory Riely, 2014 .

LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY

M. Kris, M. Socinski, J. Soria, 2014 .

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients

M Paesmans, O. Molinier, M. Paesmans, 2004, British Journal of Cancer.

[Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV? Results of a randomized study].

E. Quoix, A. Ducoloné, G. Pauli, 1991, Bulletin du cancer.

Post-operative survival of patients with lung cancer.

E. Quoix, 2016, The Lancet. Oncology.

[Epidemiological novelties in lung cancer].

E. Quoix, E. Lemarié, 2011, Revue des maladies respiratoires.

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)

E. Quoix, B. Mennecier, G. R. Ferretti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial

J. Pujol, G. Zalcman, E. Bergot, 2019, Cancers.

Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review.

E. Quoix, B. Mennecier, B. Gourieux, 2016, Lung cancer.

B. Milleron, O. Molinier, G. Zalcman, 2016, European Respiratory Journal.

New Aspects in the Epidemiology of Lung Cancer — The Women’s Epidemic

E. Quoix, 2007 .

The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma.

A Charloux, A. Charloux, H. Kreisman, 1997, International journal of epidemiology.

Determination of navelbine and desacetylnavelbine in biological fluids by high-performance liquid chromatography.

E. Quoix, H. Monteil, F. Jehl, 1990, Journal of chromatography.

Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.

E. Quoix, F. Breillout, D. Levêque, 1991, Cancer research.

An update on European randomized studies in non-small cell lung cancer.

G. Giaccone, U. Gatzemeier, R. Rosell, 1998, Seminars in Oncology.

OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)

N. Girard, O. Molinier, D. Moro-Sibilot, 2017 .

Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer.

E. Lemarié, B. Milleron, D. Moro-Sibilot, 2010 .

An ongoing randomized study of neoadjuvant chemotherapy in resectable non-small cell lung cancer.

B. Milleron, C. Chastang, D. Moro, 1994, Seminars in oncology.

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study

C. Mascaux, C. Borg, D. Vernerey, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastric distension is a contributing factor to pneumonia after pulmonary resection.

E. Quoix, M. Puyraveau, N. Santelmo, 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.

N. Girard, E. Devin, J. Muir, 2022, The Lancet. Oncology.

Positive skin tests to aero‐allergens and month of birth

E. Quoix, M. Kopferschmitt‐Kubler, G. Pauli, 1988, Allergy.

Prediction of mite allergen levels by guanine measurements in house-dust samples.

E. Quoix, G. Pauli, J. Mao, 1994, Allergy.

Prediction of mite allergen levels by guanine measurements in house‐dust samples

E. Quoix, G. Pauli, J. Mao, 1993 .

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

M. Buyse, R. Ramlau, E. Stoelben, 2011, The Lancet. Oncology.

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

E. Felip, J. Adam, A. Szczesna, 2016, The Lancet. Oncology.

105PDTG4010 IMMUNOTHERAPY COMBINED WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). PHASE 2B RESULTS OF THE TIME STUDY

J. Nemunaitis, J. Limacher, E. Quoix, 2015 .

TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

L. Sequist, J. Nemunaitis, E. Juhász, 2014, Journal of Immunotherapy for Cancer.

TG4010: A therapeutic vaccine against MUC1 expressing tumors.

J. Limacher, E. Quoix, 2012, Oncoimmunology.

Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.

H. Groen, M. Socinski, E. Smit, 2017 .

Complete response following preoperative chemotherapy for resectable non-small cell lung cancer: accuracy of clinical assessment using the French trial database.

B. Milleron, D. Moro-Sibilot, E. Quoix, 2005, Chest.

[Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].

E. Quoix, B. Mennecier, E. Chatron, 2016, Revue de pneumologie clinique.

O-211 5-year results of the French randomized study comparing preoperative chemotherapy followed by surgery and primary surgery in resectable stage I (except T1N0), II and IIIA non-small cell lung cancer

E. Lemarié, B. Milleron, D. Moro-Sibilot, 2003 .

Time to give a rest to cetuximab in the treatment of advanced non-small cell lung carcinoma?

E. Quoix, V. Westeel, 2018, Journal of thoracic disease.

Topotecan in the treatment of relapsed small cell lung cancer

E. Quoix, 2008, OncoTargets and therapy.

Concurrent chemoradiation for elderly patients with locally advanced non-small-cell lung cancer: still a controversial issue

B. Milleron, E. Quoix, V. Westeel, 2012 .

1302PDIFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)

N. Girard, O. Molinier, D. Moro-Sibilot, 2017 .

ZD0473 treatment in lung cancer: an overview of the clinical trial results.

E. Lemarié, M. Edelman, R. Ramlau, 2002, European journal of cancer.

Can we predict very short term survival in small cell lung cancer?

G. Hédelin, A. Charloux, E. Quoix, 1993, Lung cancer.

Small cell lung cancer: patients surviving longer than thirty months. Groupe d'oncologie de langue française.

B. Milleron, E. Brambilla, D. Moro, 1994, Anticancer research.

[Novel epidemiology in lung cancer - non-smokers, women and cannabis].

E. Quoix, 2007, Revue des maladies respiratoires.

Brief report : High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC : results from the IFCT Predict.amm study.

M. Copin, D. Moro-Sibilot, F. Barlesi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Superior sulcus non small cell lung carcinoma: retrospective analysis of 42 patients

E. Quoix, G. Noël, N. Santelmo, 2014, Radiation Oncology.

[IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer].

B. Milleron, S. Laporte, J. Trédaniel, 2007, Revue des maladies respiratoires.

Risk factors for early mortality and morbidity after pneumonectomy: a reappraisal.

E. Quoix, N. Santelmo, G. Massard, 2009, The Annals of thoracic surgery.

Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy.

E. Quoix, X. Ducrocq, N. Santelmo, 2008, The Annals of thoracic surgery.

Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy.

A. Purohit, E. Quoix, G. Pauli, 2000, Lung cancer.

Metastatic tumours

E. Quoix, 2019, ERS Handbook Respiratory Medicine.

Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

G. Giaccone, E. Smit, P. Postmus, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of magnetic beads for plasma cell-free DNA extraction: toward automation of plasma DNA analysis for molecular diagnostics.

M. Gaub, E. Guérin, E. Quoix, 2003, Clinical chemistry.

Use of Magnetic Beads for Plasma Cell-free DNA Ex- traction: Toward Automation of Plasma DNA Analysis

M. Gaub, E. Guérin, E. Quoix, 2003 .

[Curative antifungal treatment of invasive pulmonary aspergillosis].

J. Limacher, E. Quoix, J. Kurtz, 1995, Revue de pneumologie clinique.

[Lung cancer in women].

E. Quoix, B. Mennecier, 2005, Revue des maladies respiratoires.

MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim phase II data.

T. Velu, E. Quoix, B. Mennecier, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim phase II data

T. Velu, E. Quoix, B. Mennecier, 2004 .

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

B. Milleron, O. Molinier, S. Laporte, 2011, The Lancet.

[Atypical metastatic site of lung adenocarcinoma].

D. Jacqmin, E. Quoix, M. Chenard, 2011, Revue de pneumologie clinique.

Platinum drugs in the treatment of non-small-cell lung cancer

E. Quoix, J. Cosaert, 2002, British Journal of Cancer.

Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

C. Rudin, M. Socinski, Gregory Riely, 2013 .

MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study

D. Ettinger, M. Kris, M. Socinski, 2017 .

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

M. Gaub, E. Guérin, E. Quoix, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

J-L Pretet, I. Bièche, J. Solassol, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation

E. Quoix, B. Mennecier, M. Beau-Faller, 2014, Case Reports in Oncology.

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01).

R. Arriagada, C. Faivre-Finn, S. Senan, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.

R. Arriagada, C. Faivre-Finn, S. Senan, 2009, The Lancet. Oncology.

ERS School Course Early-stage lung cancer - What's new in the epidemiology of lung cancer: the female aspect

E. Quoix, B. Mennecier, E. Quoix, 2006, Breathe.

IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype

B. Milleron, J. Soria, D. Moro-Sibilot, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification

M. Gaub, J. Ghnassia, E. Quoix, 2015, Pathology.

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early–stage lung cancer patients from the IFCT-0002 Phase 3 Trial

F. Galateau-Sallé, E. Brambilla, O. Molinier, 2016, Oncotarget.

Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.

J. Soria, J. Mazières, G. Zalcman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial

P. Hainaut, B. Milleron, E. Brambilla, 2012, Clinical Cancer Research.

No impact of passive smoke on the somatic profile of lung cancers in never-smokers

G. Zalcman, P. Dumont, P. Souquet, 2015, European Respiratory Journal.

High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway

E. Brambilla, J. Camonis, J. Pujol, 2012, Molecular Cancer Therapeutics.

Molecular Medicine in Practice High TUBB 3 Expression , an Independent Prognostic Marker in Patients with Early Non – Small Cell Lung Cancer Treated by Preoperative Chemotherapy , Is Regulated by KRas Signaling Pathway

E. Brambilla, J. Camonis, J. Pujol, 2012 .

TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC).

J. Nemunaitis, T. Burzykowski, E. Quoix, 2012 .

Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.

A. Purohit, E. Quoix, G. Pauli, 1998, Lung cancer.

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer

R. Ramlau, M. Krzakowski, E. Tartour, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Systemic treatment of elderly patients

E. Quoix, C. Leduc, 2015 .

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

J. Lafitte, L. Freitag, J. von Pawel, 2008, British Journal of Cancer.

[Pituitary metastases from lung cancer. Five cases].

J. Schlienger, E. Quoix, B. Mennecier, 2006, Revue de pneumologie clinique.

An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928).

H. Groen, J. Rigas, S. Novello, 2016 .

Erlotinib: Another Candidate for the Therapeutic Drug Monitoring of Targeted Therapy of Cancer? A Pharmacokinetic and Pharmacodynamic Systematic Review of Literature

T. Buclin, L. Decosterd, Nicolas Widmer, 2015, Therapeutic drug monitoring.

SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients

E. Guérin, E. Quoix, M. Chenard, 2018, Cancer medicine.

Chemoradiotherapy-induced esophagitis pain relieved by topical morphine: three cases.

L. Beretz, E. Quoix, B. Mennecier, 2005, Journal of pain and symptom management.

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

S. Kaasa, P. Ganz, F. Chauvin, 1993, The Lancet.

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial.

E. Lemarié, B. Milleron, C. Chastang, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

First-Line Afatinib plus Cetuximab for EGFR-Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study

O. Molinier, M. Denis, D. Moro-Sibilot, 2021, Clinical Cancer Research.

Weekly Paclitaxel Combined with Monthly Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study

B. Milleron, O. Molinier, J. Pujol, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Preoperative C hemotherapy F ollowed b y S urgery C ompared With P rimary S urgery i n R esectable S tage I ( Except T1N0), I I, a nd I IIa N on-Small-Cell L ung C ancer

E. Lemarié, B. Milleron, L. Thiberville, 2002 .

Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.

E. Lemarié, B. Milleron, L. Thiberville, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma.

R. Arriagada, J. Douillard, T. le Chevalier, 1992, Journal of the National Cancer Institute.

Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.

R. Arriagada, J. Douillard, T. Chevalier, 1991, Journal of the National Cancer Institute.

EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up

M. Gaub, E. Guérin, E. Quoix, 2008, European Respiratory Journal.

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3

J. Pignon, C. Chouaid, E. Quoix, 2011, European Respiratory Journal.

[Current review apropos of a case of unilateral agenesis of the pulmonary artery].

E. Quoix, G. Burghard, R. Seibert, 1984, Revue de pneumologie clinique.

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

D. Ettinger, F. Cappuzzo, E. Smit, 2016, ESMO Open.

Pulmonary Migratory Infiltrates and Pachypleuritis in a Patient with Crohn’s Disease

E. Quoix, B. Gasser, G. Pauli, 2000, Respiration.

Plasma DNA microsatellite panel as sensitive and tumor‐specific marker in lung cancer patients

M. Gaub, E. Quoix, E. Weitzenblum, 2003, International journal of cancer.

Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis.

H. Groen, D. Planchard, J. Mazières, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.

J. Nemunaitis, E. Felip, L. Crinò, 2015 .

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

O. Molinier, J. Mazières, G. Zalcman, 2015, Lung cancer.

A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).

E. Lemarié, B. Milleron, O. Molinier, 2013, European journal of cancer.

Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.

N. Girard, B. Milleron, J. Douillard, 2010, Lung cancer.

A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.

F. Schramel, E. Quoix, R. Gervais, 2005, Lung cancer.

Quality Improvement Guidelines for Bone Tumour Management

A. Gangi, G. Tsoumakidou, X. Buy, 2010, CardioVascular and Interventional Radiology.

Comorbidities in the management of patients with lung cancer

A. Charloux, E. Quoix, P. Falcoz, 2017, European Respiratory Journal.

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials

B. Milleron, O. Molinier, G. Zalcman, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

KRAS‐specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non–small‐cell Lung Cancer

E. Quoix, M. Chenard, B. Mennecier, 2018, Clinical lung cancer.

Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications.

J. Pignon, F. André, A. Dujon, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.

B. Milleron, J. Trédaniel, G. Zalcman, 2016, European journal of cancer.

Astro plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients

R. Arriagada, J. Pignon, J. Douillard, 1991 .

Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure.

A. Chaouat, E. Quoix, E. Weitzenblum, 1995, Chest.

[Retrospective study of a series of 26 carcinomatous meningitis secondary to lung cancer].

E. Quoix, G. Pauli, V. Hammerer, 2005, Bulletin du cancer.

Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE.

E. Andrès, V. Poindron, A. Korganow, 2016, Joint, bone, spine : revue du rhumatisme.

Optimal Pharmacotherapeutic Strategies for Elderly Patients with Advanced Non-Small Cell Lung Cancer

E. Quoix, 2011, Drugs & aging.

Unusual presentations of lung cancer: Case 3. Paraneoplastic digital necrosis in a patient with small-cell lung cancer.

E. Quoix, G. Pauli, E. Grosshans, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Critically ill cancer patient’s resuscitation: a Belgian/French societies’ consensus conference

V. Durieux, T. Berghmans, A. Meert, 2021, Intensive Care Medicine.

[Multiple complications of a mycoplasma pneumoniae infection].

A. Charloux, E. Quoix, G. Pauli, 1993, Revue des maladies respiratoires.

Migratory pulmonary infiltrates in a patient treated with sotalol.

A. Gangi, E. Quoix, B. Gasser, 1997, The European respiratory journal.

Effects of Chemoradiotherapy on Pancreatic Cancer

R. Arriagada, E. Quoix, P. Ruffle, 2019 .

Impact of 3 D Conformal Radiotherapy on Lung Function of Patients with Lung Cancer : A Prospective Study

A. Charloux, E. Quoix, B. Mennecier, 2013 .

Impact of 3D Conformal Radiotherapy on Lung Function of Patients with Lung Cancer: A Prospective Study

A. Charloux, E. Quoix, B. Mennecier, 2012, Respiration.

Can exhaled NO fraction predict radiotherapy-induced lung toxicity in lung cancer patients?

A. Charloux, E. Quoix, B. Gény, 2012, Radiation oncology.

Lung Cancer in Older Adults: Systemic Treatment

E. Quoix, 2020, Geriatric Oncology.

Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial

J. Limacher, C. Rotonda, F. Bonnetain, 2015, PloS one.

1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial

G. Giaccone, D. Galetta, E. Felip, 2020, Annals of Oncology.

[Disseminated intravascular coagulation syndrome and thromboembolic complications of non-small-cell lung cancer. A case report].

E. Quoix, B. Mennecier, G. Pauli, 2007, Revue de pneumologie clinique.

E. Quoix, B. Mennecier, L. Bender, 2019, Annals of translational medicine.

Specific Features of Non-small Cell Lung Cancer in Women: A Retrospective Study of 1738 Cases Diagnosed in Bas-Rhin between 1982 and 1997

G. Hédelin, A. Purohit, E. Quoix, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma.

R. Arriagada, J. Douillard, T. le Chevalier, 1994, Lung cancer.

Long-term survivors of small-cell lung cancer (SCLC): A French multicenter study

J. Lafitte, B. Milleron, E. Brambilla, 1997 .

Anticorps anti-pseudo-PCNA de type 1 (anti-SG2NA) : cherchez un cancer, pas le lupus ☆

E. Andrès, V. Poindron, A. Korganow, 2017 .

Should we screen patients for carotid artery disease before lung cancer resection?

A. Charloux, E. Quoix, P. Falcoz, 2020, Journal of thoracic disease.

Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.

O. Molinier, J. Pujol, P. Dumont, 2020, European journal of cancer.

Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG).

M. Aapro, J. Michel, C. Walko, 2015, European journal of cancer.

Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504

G. Zalcman, D. Moro-Sibilot, F. Barlesi, 2015, European Respiratory Journal.

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer

B. Milleron, O. Molinier, J. Trédaniel, 2013, European Respiratory Journal.

Advanced non-small cell lung cancer in elderly patients

E. Quoix, 2012, Breathe.

Therapeutic options in older patients with metastatic non-small cell lung cancer

E. Quoix, 2012, Therapeutic advances in medical oncology.

Chemotherapy in elderly patients with advanced non-small cell lung cancer.

B. Milleron, G. Zalcman, E. Quoix, 2011, Lung cancer.

Non-small-cell lung cancer in a French department, (1982–1997): management and outcome

G. Hédelin, A. Purohit, E. Quoix, 2005, British Journal of Cancer.

Problems in radiographic estimation of response to chemotherapy and radiotherapy in small cell lung cancer

H. Kreisman, E. Quoix, N. Wolkove, 1988, Cancer.

Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.

R. Ramlau, M. Krzakowski, A. Santoro, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised Phase II study of topotecan/cisplatin versus topotecan/etoposide in patients with untreated, extensive disease, small cell lung cancer (SCLC)

F. Schramel, E. Quoix, R. Gervais, 2000 .

1273OResults of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)

E. Devin, J. Lafitte, J. Trédaniel, 2017 .

Inability of serum neuron-specific enolase to predict disease extent in small cell lung cancer.

A. Charloux, E. Quoix, G. Pauli, 1993, European journal of cancer.

A high lymph node ratio predicts loco-regional recurrence while microscopic N2 predicts survival after radiation therapy in pIIIA-N2 non-small cell lung cancer

E. Quoix, G. Noël, N. Santelmo, 2015, Journal of Radiation Oncology.

Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

J. Pujol, M. Tanguy, E. Quoix, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

4′epidoxorubicin (Epi DX) in elderly or unfit patients (pts) with small cell lung cancer (SCLC): a phase II experience by the EORTC Lung Cancer Cooperative Group

J. Jassem, N. Zandwijk, E. Quoix, 1991 .

O-64 Long term results in terms of neurotoxicity among patients with limited small cell lung cancer included in a trial evaluating prophylactic cranial irradiation

R. Arriagada, T. Chevalier, A. Laplanche, 2003 .

Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study.

A. Purohit, E. Quoix, M. Velten, 2015, Clinical lung cancer.

[Lung cancer and pollution].

E. Quoix, B. Mennecier, 2003, Revue de Pneumologie Clinique.

[Specific features of bronchial cancer in women].

E. Quoix, 1999, Revue de Pneumologie Clinique.

[Do patients with squamous cell carcinoma or adenocarcinoma of the lung have different smoking histories?].

G. Hédelin, A. Charloux, A. Purohit, 1999, Revue des maladies respiratoires.

Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.

B. Milleron, D. Moro-Sibilot, E. Quoix, 2005, Journal of the National Cancer Institute.

Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: a multicenter phase II study.

B. Milleron, E. Quoix, A. Depierre, 2006, Lung cancer.

Chemotherapy in advanced nonsmall cell lung cancer

E. Quoix, 2009 .

Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping

M. Gaub, E. Guérin, E. Quoix, 2009, British Journal of Cancer.

Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on lung cancer screening.

N. Girard, F. Laurent, M. Revel, 2021, Diagnostic and interventional imaging.

Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors

F. André, J. Pujol, T. Chevalier, 2001, British Journal of Cancer.

Superior sulcus non small cell lung carcinoma: retrospective analysis of 42 patients

E. Quoix, G. Noël, N. Santelmo, 2014, Radiation oncology.

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.

C. Gridelli, V. Georgoulias, E. Smit, 2010, European journal of cancer.

Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group.

G. Giaccone, J. Jassem, N. van Zandwijk, 1992, European Journal of Cancer.

A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): An intergroup study FNCLCC Cleo04 - IFCT 00-01.

J. Pujol, M. Tanguy, E. Quoix, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

E Pichon, B. Milleron, G. Zalcman, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A left pleural effusion with a calcified tumoral mass and left hemithoracic uptake on bone scan.

E. Quoix, M. Chenard, G. Lang-Avérous, 2001, Lung cancer.

Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010.

R. Ramlau, J. Limacher, E. Quoix, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies

B. Duclos, L. Fornecker, P. Barthélémy, 2014, Oncology.

Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer

J. Vansteenkiste, P. Zatloukal, N. Dohollou, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Is there a role for e-cigarettes in smoking cessation?

E. Quoix, C. Leduc, 2016, Therapeutic advances in respiratory disease.

Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.

M. Edelman, Chun-Ming Tsai, Heung Tae Kim, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Standards, Options and Recommendations for the management of non-small cell lung carcinoma patients].

E. Touboul, T. Molina, E. Lemarié, 2003, Bulletin du cancer.

[Endobronchial aspergillosis associated with a carcinoid tumor].

E. Quoix, B. Gasser, G. Pauli, 1990, Revue des maladies respiratoires.

Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma.

P. Berthaud, T. le Chevalier, J. Bérille, 1989, European journal of cancer & clinical oncology.

Diagnosis of Jejunal Metastases from Lung Cancer Using Capsule Endoscopy

A. Gangi, M. Delvaux, E. Quoix, 2016, Case Reports in Oncology.

[Thyroid metastasis of lung cancer and abnormal thyroid function--a case report].

E. Quoix, B. Mennecier, G. Massard, 2009, Revue de pneumologie clinique.

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials

B. Milleron, O. Molinier, G. Zalcman, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.

E. Lemarié, B. Milleron, J. Pujol, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

IFCT0002 phase III study comparing a preoperative (PRE) and a perioperative (PERI) chemotherapy with two different CT regimens in resectable non-small cell lung cancer (NSCLC): Early results

B. Milleron, J. Pujol, E. Quoix, 2007 .

Comparison between Der p I plus Der f I content determinations and guanine measurements in 239 house dust samples.

E. Quoix, G. Pauli, J. Bessot, 1991, Journal of Allergy and Clinical Immunology.

Postoperative follow-up of lung cancer: Randomized trial comparing two follow-up programs in completely resected non-small cell lung cancer (IFCT-0302).

E. Devin, J. Lafitte, J. Trédaniel, 2012 .

Results of the IFCT 0002 phase III study comparing a preoperative and a perioperative chemotherapy (CT) with two different CT regimens in resectable non-small cell lung cancer (NSCLC).

B. Milleron, J. Pujol, E. Quoix, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Bronchiolitis obliterans with organizing pneumonia. Retrospective study of 19 cases].

E. Quoix, A. Vandevenne, E. Weitzenblum, 1998, Revue de Pneumologie Clinique.

Perception of Lung Cancer among the General Population and Comparison with Other Cancers

B. Milleron, J. Mazières, J. Pujol, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CT lung cancer screening: where are we heading to?

B. Milleron, E. Quoix, B. Mennecier, 2014 .

Phase III randomized study of Neo-Adjuvant chemotherapy surgery in non-small cell lung cancer (NSCLC) preliminary results

E. Lemarié, B. Milleron, C. Chastang, 1994 .

Prognostic factors for survival in extensive stage small cell lung cancer.

E. Quoix, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A two-faced young woman.

E. Quoix, B. Mennecier, M. Jeung, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of gemcitabine-oxaliplatin or gemcitabine-cisplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC)-CLEO 05.

J. Pujol, T. le Chevalier, X. Sun, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alvéolite neutrophilique due à la minocycline

E. Quoix, G. Pauli, G. Fourgaut, 2004 .

[Minocycline-induced neutrophilic alveolitis?].

E. Quoix, G. Pauli, G. Fourgaut, 2004, Revue de Pneumologie Clinique.

1827P European Society for Medical Oncology (ESMO)/International Society of Geriatric Oncology (SIOG) Joint Working Group (WG) survey on management of older patients with cancer

H. Wildiers, C. Steer, R. Kanesvaran, 2021, Annals of Oncology.

Comorbidities in the management of patients with lung cancer

A. Charloux, E. Quoix, P. Falcoz, 2017, European Respiratory Journal.

[Recommendations of French specialists on screening for lung cancer].

N. Girard, F. Laurent, M. Revel, 2021, Revue des maladies respiratoires.

Carcino-sarcome bronchopulmonaire

E. Quoix, B. Gasser, G. Pauli, 1998 .

[What is new in the epidemiology of lung cancer: non-smokers, women and the role of cannabis?].

E. Quoix, 2009, La Revue du praticien.